Managed Entry Agreements For Pharmaceuticals In Australia

In addition, as soon as a product has been made available to patients, paying agencies have indicated that once a product has been made available to patients, it has been excluded from the list where the evidence is no longer impossible to cover due to the lack of mechanisms facilitating delisting and weak social support for the withdrawal of reimbursement decisions based on economic evidence. These results have implications for health sector stakeholders, as while results-based management agreements are needed to facilitate market access, there is a need to address the lack of infrastructure in many countries, which would easily facilitate data collection, and to identify viable models and mechanisms. Keywords: managed entry agreements; results-based agreements; performance agreements; Pharmaceutical policy.